儿童肾移植术后激素撤离保护策略对身高生长影响的对照研究
前瞻性队列研究纳入40例儿童肾移植受者,按原发病分为激素撤离组(25例)和激素维持组(15例)。激素撤离组术后第2年身高追赶速率ΔHtSDS显著大于维持组,第24个月HtSDS显著更高,且两组抗体介导性排斥反应发生率无显著差异。
要点
- 激素撤离组单位体重GC剂量显著低于维持组。
- 术后第2年激素撤离组ΔHtSDS显著大于维持组。
- 两组抗体介导性排斥反应发生率无显著差异。
核心结论
- 儿童肾移植后早期采取激素撤离保护策略有利于追赶性纵向生长。
- 早期撤离激素不会增加术后抗体介导的免疫排异反应的发生风险。
研究设计与样本
- 前瞻性队列研究,纳入2017年7月至2022年9月广州市妇女儿童医疗中心40例慢性肾脏病5期肾移植患儿。
- 术前原发病为免疫相关性肾小球疾病或病因不明者入激素维持组(15例),遗传性肾脏病或先天性泌尿系畸形者入激素撤离组(25例)。
- 激素维持组术后3个月内激素逐渐减量至2.5~5.0 mg/d维持,激素撤离组术后3个月内激素逐渐减量至停药。
- 在基线及移植后6、12、18、24个月记录生长数据及临床资料,总体随访时间(26±12)个月。
主要发现
- 激素撤离组单位体重GC剂量明显低于激素维持组[(0.13±0.06)比(0.36±0.19)mg/(kg·d),t=5.83,P<0.001]。
- 术后第1年激素撤离组ΔHtSDS为1.0(0.7,1.4),激素维持组为0.4(0.1,1.0)。
- 术后第2年激素撤离组ΔHtSDS明显大于激素维持组[1.1(0.2,1.7)比0.3(0,0.8),U=28.00,P=0.039]。
- 激素撤离组和激素维持组在5个随访时间点之间的HtSDS分别为-2.5±0.8、-2.0±0.8、-1.5±0.8、-1.3±0.9、-0.5±0.3和-2.4±1.3、-2.2±1.1、-2.0±1.0、-1.8±1.0、-1.6±1.0,差异有统计学意义(F=19.81,P<0.01),但两组间HtSDS整体效应差异无统计学意义(F=1.13,P=0.204),激素的使用与随访时间的增加有交互作用(F=3.62,P=0.009)。
- 移植后第24个月,激素撤离组终点HtSDS明显高于激素维持组(t=2.13,P=0.047)。
临床怎么用
- 儿童肾移植后对遗传性肾脏病或先天性泌尿系畸形患儿可考虑早期激素撤离以促进追赶性生长。
- 激素撤离策略未增加抗体介导性排斥反应风险,但仍需监测排斥反应。
局限性
- 研究为单中心前瞻性队列,样本量40例,激素撤离组与维持组分组基于原发病而非随机化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To study the influence of steroid withdrawal protection strategy on height growth in pediatric patients after kidney transplantation. Methods: The prospective cohort study enrolled 40 stage 5 chronic kidney disease children receiving kidney transplantation from July 2017 to September 2022 at Guangzhou Women and Children's Medical Center. Based on the primary preoperative disease, patients with immune abnormality-associated glomerular diseases or unknown causes were assigned to the steroid maintenance group, in which patients received steroid tapering within 3 months after surgery to a maintenance dose of 2.5 to 5.0 mg/d. While patients with hereditary kidney disease or congenital urinary malformations were assigned to the steroid withdrawal group, in which patients had steroids tapered off within 3 months. The characteristics of height catch-up growth and clinical data were compared between the 2 groups at baseline, 6, 12, 18 and 24 months after kidney transplantation. T-test, repeated measurement of variance analysis, Mann-Whitney U test, and Fisher exact test were used for the comparison between the 2 groups. Results: Among the 40 children, 17 were males, 23 were females, 25 were in the steroid withdraw group ((7.8±2.8) years old when receiving kidney transplantation) and 15 cases were in the steroid maintenance group ((7.6±3.5) years old when receiving kidney transplantation). The study population was followed up for (26±12) months. The total dose per unit body weight of steroids in the steroid withdrawal group was lower than that in the steroid maintenance group ((0.13±0.06) vs. (0.36±0.19) mg/(kg·d), t=5.83, P<0.001). The height catch-up rate (ΔHtSDS) in the first year after kidney transplantation in the steroid withdraw and steroid maintenance groups was 1.0 (0.7, 1.4) and 0.4 (0.1, 1.0), respectively; in the second year, the ΔHtSDS in the steroid withdraw group was significantly higher than that in the steroid maintenance group (1.1 (0.2, 1.7) vs. 0.3 (0, 0.8), U=28.00, P=0.039). The HtSDS in the steroid withdrawal group at the five follow-up time points was -2.5±0.8, -2.0±0.8, -1.5±0.8, -1.3±0.9 and -0.5±0.3, respectively, while in the steroid maintenance was -2.4±1.3, -2.2±1.1, -2.0±1.0, -1.8±1.0 and -1.6±1.0, respectively. There were statistically significant differences in HtSDS at different follow-up time points in both 2 groups (F=19.81, P<0.01), but no statistical differences in overall impact between the 2 groups (F=1.13, P=0.204). The steroid treatment was interaction with the increase of follow-up time (F=3.62, P=0.009). At the 24th month after transplantation, the HtSDS in the steroid withdrawal group was significantly higher than that in the steroid maintenance group (P=0.047). Six patients in the steroid withdrawal group experienced antibody-mediated immune rejection (AMR), while 3 did in the steroid maintenance group. Moreover, there was no significant difference in AMR between the two groups (χ2=0.06, P=0.814). Conclusion: The steroid withdrawal protection strategy favors the height catch-up growth in pediatric patients after kidney transplantation and does not increase the risk of postoperative antibody-mediated immune rejection. 目的: 探讨糖皮质激素(GC)撤离保护策略对儿童肾移植术后身高生长的影响。 方法: 前瞻性队列研究。以2017年7月至2022年9月由广州市妇女儿童医疗中心提供并已接受同种异体肾移植手术的40例慢性肾脏病5期患儿为研究对象,术前原发病免疫相关性肾小球疾病或病因不明的患儿为激素维持组,遗传性肾脏病或先天性泌尿系畸形的患儿为激素撤离组。激素维持组采用激素维持法,术后3个月内激素逐渐减量至低剂量(2.5~5.0 mg/d)维持。激素撤离组采用激素撤离法,术后3个月内激素逐渐减量至停药。在基线及移植后6、12、18、24个月记录两组患儿生长数据及临床资料。组间比较采用t检验、重复测量资料方差分析、Mann-Whitney U检验或Fisher 确切概率法。 结果: 40例患儿中男17例、女23例,激素撤离组25例[移植年龄(7.8±2.8)岁],激素维持组15例[移植年龄(7.6±3.5)岁],总体随访时间(26±12)个月。激素撤离组单位体重GC剂量明显低于激素维持组[(0.13±0.06)比(0.36±0.19)mg/(kg·d),t=5.83,P<0.001]。术后第1年激素撤离组身高追赶速率(ΔHtSDS)为1.0(0.7,1.4),激素维持组为0.4(0.1,1.0);第2年激素撤离组ΔHtSDS明显大于激素维持组[1.1(0.2,1.7)比0.3(0,0.8),U=28.00,P=0.039]。激素撤离和激素维持组在5个随访时间点之间的HtSDS分别为-2.5±0.8、-2.0±0.8、-1.5±0.8、-1.3±0.9、-0.5±0.3和-2.4±1.3、-2.2±1.1、-2.0±1.0、-1.8±1.0、-1.6±1.0,差异有统计学意义(F=19.81,P<0.01),但两组间HtSDS整体效应差异无统计学意义(F=1.13,P=0.204),激素的使用与随访时间的增加有交互作用(F=3.62,P=0.009)。在移植后第24个月,激素撤离组终点身高标准差积分明显高于激素维持组(t=2.13,P=0.047)。激素撤离组发生抗体介导性排斥反应(AMR)有6例,激素维持组有3例,两组AMR发生率差异无统计学意义(χ2=0.06,P=0.814)。 结论: 儿童肾移植后早期采取激素撤离保护策略有利于追赶性纵向生长,对于肾移植术后儿童早期撤离激素不会增加术后抗体介导的免疫排异反应的发生风险。.
引用
- Lu JY, Zhang M, Lin JA, et al. [A control study of steroid withdrawal protection strategy after kidney transplantation in children]. Zhonghua Er Ke Za Zhi. 2023. PMID: 37650161. doi:10.3760/cma.j.cn112140-20230212-00097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。